Key takeaways

PT-141 (bremelanotide) is a peptide that works on sexual desire through the central nervous system — a fundamentally different mechanism than PDE5 inhibitors like tadalafil or sildenafil, which work on blood flow. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women under the brand name Vyleesi, and used off-label in men and in postmenopausal women. The most common side effect is nausea — manageable, but real. Here is what the evidence shows and who is a good candidate.

Most medications for sexual function work from the neck down — they address the mechanics, not the desire. PT-141 works from the other direction. It activates specific receptors in the brain that are responsible for sexual arousal, not just blood flow.

For the subset of men and women whose primary concern is low desire — not performance — this distinction matters. PT-141 is not a replacement for PDE5 inhibitors. It is a different tool, addressing a different part of the picture.

Here is what the clinical evidence shows about how it works, how well it works, and what the nausea risk actually looks like in practice.

What PT-141 Is and How It Works

PT-141, also known as bremelanotide, is a non-selective melanocortin receptor agonist that exerts its sexual-function effects primarily through MC3R and MC4R activation in the central nervous system. These receptors are involved in pathways that regulate sexual arousal and desire. Activation triggers the release of dopamine, norepinephrine, and oxytocin in brain regions associated with sexual response. Activation of MC1R, which sits in the same receptor family, is thought to contribute to the skin-pigmentation side effects discussed below.

This is mechanistically distinct from how PDE5 inhibitors work. Sildenafil and tadalafil relax smooth muscle in blood vessel walls to improve blood flow. PT-141 does not affect blood flow directly. It changes what the brain is doing — which is why it can support desire in people whose vascular function is intact but whose interest has flattened, and why it can complement PDE5 inhibitors in men whose response to those medications alone has been incomplete.

FDA Status: Approved for One Use, Used for Others

PT-141 received FDA approval in June 2019 as Vyleesi, indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That remains the only formally approved indication in the United States.

Off-label use in men and in postmenopausal women is common in clinical practice. The FDA's 2019 approval was specifically for premenopausal women — the postmenopausal population was deliberately not in the approval-supporting trials — so use in those groups, while supported by clinical experience and adjacent trial data, sits in a different evidentiary category from the labeled use.

Evidence in Women

PT-141's FDA approval was based on two large Phase 3 trials in premenopausal women with HSDD. The headline findings: a statistically significant improvement in measures of sexual desire and a reduction in distress associated with low desire, compared with placebo, over 24 weeks of use.

The clinical reality is that the effect size is modest in averaged trial data — but for individual responders, the change can be meaningful. PT-141 tends to work clearly or not at all, rather than producing a small partial response in most users.

In postmenopausal women, off-label use is supported by smaller studies and clinical experience. Women in perimenopause and postmenopause often combine PT-141 with topical or low-dose systemic hormone therapy, addressing both the neurological and the hormonal components of low desire.

Evidence in Men

The men's clinical trial program for bremelanotide predated FDA approval and was conducted with the intranasal formulation at substantially higher doses than the currently FDA-approved 1.75 mg subcutaneous formulation used for HSDD in women. In the Safarinejad 2008 Journal of Urology trial of 342 sildenafil non-responders, 33.5% of men receiving intranasal bremelanotide 10 mg reported a meaningfully better erectile response — including the ability to achieve and maintain an erection sufficient for intercourse — compared with 8.5% on placebo (p=0.03). It is important to note that these trials used a different formulation and dose than the currently FDA-approved subcutaneous form.

The most clinically interesting finding for men: in studies of men who responded inadequately to sildenafil alone, adding PT-141 produced significantly better erectile response than sildenafil alone. PT-141 is best understood as an option for non-responders or partial responders to PDE5 inhibitors, or for men whose primary concern is low desire rather than mechanical erectile function.

Side Effects — Addressing the Nausea Question Honestly

About 40% of users in clinical trials experienced nausea. This is the single most common reason people discontinue PT-141. The nausea is dose-related and typically peaks 30–60 minutes after injection. It is manageable, but it is not minor — anyone considering PT-141 should be prepared for it as a real possibility.

Strategies that help: starting at a lower dose than the standard 1.75 mg subcutaneous, taking ondansetron as a pre-treatment if a physician agrees, and timing use for an evening when the nausea window will pass before activity. Honest framing of the trial data: in the RECONNECT trials supporting FDA approval, the nausea-related discontinuation rate was approximately 7–8% — substantially lower than the 40% any-nausea incidence figure suggests on its own.

Other common side effects (per the FDA Vyleesi prescribing information):

Flushing (about 20% of users)

Headache (about 11%)

Injection site reactions (about 13%)

Transient blood pressure elevation (typically about 6 mmHg systolic, peaking around 4 hours and resolving by 8–10 hours)

Skin hyperpigmentation, particularly on the face, breasts, and gums. This is the MC1R-mediated side effect — it can be more visible in people with darker skin tones and may not fully reverse after stopping the medication. Worth a direct conversation before starting.

Two interaction notes worth knowing: PT-141 should be used cautiously with alcohol, which can amplify orthostatic effects, and it can reduce the effectiveness of oral naltrexone for opioid use disorder.

PT-141 is not appropriate for people with uncontrolled high blood pressure or known cardiovascular disease. Discussing your current medications and conditions with a physician is the standard before any first dose.

Dosing and Practical Use

The standard FDA-approved formulation is a 1.75 mg subcutaneous injection from a prefilled autoinjector. Administration is in the abdomen or thigh, typically 45 minutes to 2 hours before activity.

Maximum dosing under the FDA-approved label is one dose per 24-hour period and no more than 8 doses per month. Most users find the right rhythm with occasional use rather than scheduled use.

Effects typically begin within 30–60 minutes and can persist for 6–24 hours depending on individual response. Wider variation in duration than with PDE5 inhibitors is part of the picture.

How Leader Health Approaches This

At Leader Health, PT-141 is offered as part of a sexual health program that considers your full picture — hormones, cardiovascular health, current medications, and individual goals. A physician reviews the plan and confirms safety before any prescription. We do not push it as a one-size-fits-all solution; it is one tool among several, and the right tool depends on what is actually limiting your sexual response.

If you have been told to try a PDE5 inhibitor and it has not fully addressed the issue, PT-141 is worth a real conversation.

References

1. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908.

2. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019. PMC8788464 — pmc.ncbi.nlm.nih.gov/articles/PMC8788464/.

3. Safarinejad MR, Hosseini SY. Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled Study. J Urol. 2008;179(3):1066-1071.

4. Diamond LE, et al. An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist. Int J Impot Res. 2004;16(1):51-9. PMID: 14963471.

5. FDA. Vyleesi (bremelanotide injection) prescribing information. accessdata.fda.gov.